Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 4/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540151 | 0.84 | BCHE (0.38) | JAK2JAK3KMT2AMAOBMRGPRX4 | |
| SCHEMBL2456978 | 0.82 | MRGPRX4 (0.40) | MAOBMRGPRX4NR4A2 | |
| SCHEMBL2460381 | 0.81 | MAOB (0.38) | MAOBMRGPRX4NR4A2 | |
| SCHEMBL2460371 | 0.80 | NR1H2 (0.42) | KMT2AMAOBMRGPRX4NR4A2 | |
| SCHEMBL2465962 | 0.80 | NR1H2 (0.42) | JAK2JAK3PPARGMEN1KMT2A | |
| SCHEMBL2462309 | 0.80 | MRGPRX4 (0.43) | JAK2JAK3MEN1KMT2AMAOB | |
| SCHEMBL2460621 | 0.79 | NR1H2 (0.39) | PPARGMRGPRX4DHODHNR4A2 | |
| SCHEMBL2459986 | 0.78 | TSHR (0.39) | HSP90AA1MAOBMRGPRX4NR4A2 | |
| SCHEMBL2458350 | 0.77 | MRGPRX4 (0.38) | MAOBMRGPRX4DHODHNR4A2 | |
| SCHEMBL2461277 | 0.77 | ALOX5 (0.40) | MRGPRX4DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957496-B1 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARM INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | JAK2 133/4885JAK3 92/4885PPARG 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.